Aquestive Therapeutics, Inc. (AQST) vs ArriVent BioPharma, Inc. (AVBP)

A side-by-side comparison of Aquestive Therapeutics, Inc. and ArriVent BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AQST

Aquestive Therapeutics, Inc.

$573M

$4.57HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT

AVBP

ArriVent BioPharma, Inc.

$689M

$14.80HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT

Total return — AQST vs AVBP

growth of $100 · dividends reinvested · last 3y

AQST +91.2% (+24.1%/yr)AVBP +42.3% (+12.5%/yr)AQST compounded faster over this window

AQST AVBP

AQST vs AVBP: by the numbers

•AVBP is the larger company ($689M vs $573M market cap).
•Both run net losses; AVBP's is the smaller (0.00% vs -144.63% net margin).

Metrics side by side

Valuation

Metric	AQST	AVBP
P/S ratio	10.59	N/A
P/B ratio	N/A	1.88

Profitability

Metric	AQST	AVBP
Gross margin	67.04%	0.00%
Operating margin	-156.36%	0.00%
Net margin	-144.63%	0.00%
ROE	N/A	-44.63%
ROIC	-45.62%	-47.96%

Growth (annualized)

Metric	AQST	AVBP
Revenue CAGR (5Y)	-0.58%	N/A
Total return CAGR (5Y)	2.24%	N/A

Go deeper

Full AQST analysis Full AVBP analysis Interactive comparison tool

Dig into the metrics

Aquestive Therapeutics ROE ArriVent BioPharma ROE Aquestive Therapeutics operating margin ArriVent BioPharma operating margin Aquestive Therapeutics revenue growth ArriVent BioPharma revenue growth Aquestive Therapeutics free cash flow ArriVent BioPharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.